HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Coonrod, J. D. Search for Related Content PubMed Articles by Coonrod, J. D.

Physical and Immunologic Properties of Pneumococcal Capsular Polysaccharide Produced during Human Infection¹

Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

Abstract

A mean molecular weight of 100,000 was found for type-specific pneumococcal capsular antigens (PCA) present in sera, bullous fluid, and pleural or cerebrospinal fluids from 11 patients with pneumococcal infection and for type-specific purified pneumococcal polysaccharide vaccines (PPP). The molecular weight of serum PCA was not decreased by trypsinization or incubation of the PCA in serum at 37°C. PCA present in the urine of individuals with pneumococcal infection was markedly smaller than PCA present in the other body fluids. Urine PCA had only partial immunologic identity with PPP and reacted differently from PPP or PCA in other body fluids in immunoelectrophoresis. These differences could not be attributed to degradation of PCA by urine per se. The mean molecular weight of circulating PCA and its immunoreactivity in gel diffusion tests did not change with time. PCA present in the urine during periods of prolonged antigenemia was persistently different from the serum PCA in gel diffusion tests and had a low molecular weight. Urine PCA from different patients infected with the same pneumococcal type were immunologically identical in double diffusion tests.

Low molecular weight PCA in the urine of individuals with pneumococcal infection may be derived from eigher selective renal excretion of low molecular weight PCA produced by the infecting pneumococci or from in vivo degradation of large molecular weight PCA produced during infection.

Footnotes

¹ This work was supported by research Grant CC 00579 from the Center for Disease Control, Atlanta, Georgia.

² Present address: Department of Medicine, Infectious Disease Division, University of Kentucky College of Medicine, Veterans Administration Hospital, Lexington, Kentucky 40507. Reprint requests should be sent to this address.